• DE - Deutsch
  • EN - English
Parliamentary question - E-002599/2019(ASW)Parliamentary question

Answer given by Mr Moedas on behalf of the European Commission

The Commission recognises the importance of research on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Under Horizon 2020, the EU Framework Programme for Research and Innovation (2014-2020)[1], the project Help4Me[2], funded via the SME Instrument, has worked on developing GutMagnific™, a probiotic designed to correct the gut microflora imbalance — linked to CFS symptoms. This innovative product could represent a life-changing promise to severely underserved population of CFS patients. Moreover, Horizon 2020 funds GLORIA[3], a project investigating the pathophysiology of chronic pain conditions, and the RTCure[4] project that aims at improving diagnostics and treatment of the rheumatic and other autoimmune diseases largely associated with fatigue and pain.

Horizon 2020 strategically supports scientific excellence using a variety of funding schemes, including bottom-up approaches, and continues to provide opportunities for research funding on ME/CFS. The Commission has proposed that Horizon Europe[5], building upon Horizon 2020, continues to support research in a flexible manner to improve the health of the European citizens and to provide further opportunities for research in ME/CFS.

Last updated: 30 October 2019
Legal notice - Privacy policy